- Home
- INSM vs PTC Comparison
INSM vs PTC Comparison
Compare INSM & PTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- PTC
- Stock Information
- Founded
- INSM 1988
- PTC 1985
- Country
- INSM United States
- PTC United States
- Employees
- INSM N/A
- PTC N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- PTC Computer Software: Prepackaged Software
- Sector
- INSM Health Care
- PTC Technology
- Exchange
- INSM Nasdaq
- PTC Nasdaq
- Market Cap
- INSM 29.0B
- PTC 24.3B
- IPO Year
- INSM 2000
- PTC 1989
- Fundamental
- Price
- INSM $162.43
- PTC $201.59
- Analyst Decision
- INSM Strong Buy
- PTC Buy
- Analyst Count
- INSM 19
- PTC 13
- Target Price
- INSM $152.71
- PTC $209.77
- AVG Volume (30 Days)
- INSM 2.2M
- PTC 740.4K
- Earning Date
- INSM 10-30-2025
- PTC 11-05-2025
- Dividend Yield
- INSM N/A
- PTC N/A
- EPS Growth
- INSM N/A
- PTC 73.27
- EPS
- INSM N/A
- PTC 4.25
- Revenue
- INSM $398,105,000.00
- PTC $2,471,978,000.00
- Revenue This Year
- INSM $32.44
- PTC $14.08
- Revenue Next Year
- INSM $123.99
- PTC $7.51
- P/E Ratio
- INSM N/A
- PTC $47.84
- Revenue Growth
- INSM 21.15
- PTC 11.42
- 52 Week Low
- INSM $60.40
- PTC $133.38
- 52 Week High
- INSM $163.22
- PTC $219.69
- Technical
- Relative Strength Index (RSI)
- INSM 80.62
- PTC 43.18
- Support Level
- INSM $156.87
- PTC $200.69
- Resistance Level
- INSM $163.22
- PTC $206.30
- Average True Range (ATR)
- INSM 4.29
- PTC 2.82
- MACD
- INSM 0.73
- PTC -0.30
- Stochastic Oscillator
- INSM 94.51
- PTC 35.59
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About PTC PTC Inc.
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America and Europe.